Galectin Therapeutics Inc.
GALT
$1.35
$0.021.51%
| Weiss Ratings | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Very Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.49 | |||
| Price History | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -11.51% | |||
| 30-Day Total Return | -8.50% | |||
| 60-Day Total Return | 22.27% | |||
| 90-Day Total Return | -50.37% | |||
| Year to Date Total Return | 14.96% | |||
| 1-Year Total Return | -64.04% | |||
| 2-Year Total Return | -33.42% | |||
| 3-Year Total Return | -15.94% | |||
| 5-Year Total Return | -23.14% | |||
| 52-Week High % Change | -68.96% | |||
| 52-Week Low % Change | 82.50% | |||
| Price | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $4.27 | |||
| 52-Week Low Price | $0.73 | |||
| 52-Week Low Price (Date) | Dec 20, 2024 | |||
| 52-Week High Price (Date) | Apr 12, 2024 | |||
| Valuation | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 83.71M | |||
| Enterprise Value | 177.06M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.76 | |||
| Earnings Per Share Growth | 1.61% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -0.79 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.35 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -4.17 | |||
| Market Cap Category | Micro Cap | |||
| Dividends and Shares | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 62.75M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 678 620 3186 | |||
| Address | 4960 Peachtree Industrial Boulevard Norcross, GA 30071 | |||
| Website | galectintherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2000 | |||
| Profitability | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -116.08% | |||
| Return on Equity | -- | |||
| Income Statement | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -- | |||
| EBIT (TTM) | -42.43M | |||
| Net Income (TTM) | -47.05M | |||
| Net Income Avl. to Common (TTM) | -47.05M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -19.71% | |||
| EPS Diluted (TTM) | -0.76 | |||
| EPS Diluted Growth (Q YOY) | -17.90% | |||
| Balance Sheet | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 15.12M | |||
| Cash Per Share (Q) | $0.24 | |||
| Total Current Assets (Q) | 17.25M | |||
| Total Preferred Equity (Q) | 2.22 | |||
| Total Equity (Q) | -103.07M | |||
| Current Ratio (Q) | 0.487 | |||
| Book Value Per Share (Q) | -$1.67 | |||
| Total Assets (Q) | 17.50M | |||
| Total Current Liabilities (Q) | 35.41M | |||
| Total Debt (Q) | 106.25M | |||
| Total Liabilities (Q) | 120.57M | |||
| Total Common Equity (Q) | -105.29M | |||
| Cash Flow | GALT - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 31.23M | |||
| Net Change in Cash (TTM) | -10.54M | |||
| Levered Free Cash Flow (TTM) | -28.94M | |||
| Cash from Operations (TTM) | -41.77M | |||
